With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc. (Nasdaq: CNXU) is positioning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results